Psychotropics

by

Hypothesis: Do Psychotropics In Treating Schizophrenia Pose A Risk In A Delayed Auditory Processing?

Spelling it out:

It’s a known fact that many people (not all!) with schizophrenia experience auditory hallucinations. Conversely, individuals on these prescribed medications in treating schizophrenia can suffer from a decline in cognition (i.e., slurred speech, reduction in thought processing, slowed gait).

It has to be emphasized these particular above-mentioned cognitive processes were healthy before medications were administered.

Thus, there is a potential argument which can suggest that a patient using medicine to treat schizophrenia may experience a side effect involving their hearing.

Research is necessary to ascertain just how devastating this health issue can become for current patients, new patients, and patients in the future, all diagnosed with schizophrenia.

Vikki

by

OCTOBER IS BREAST CANCER AWARENESS MONTH*

Women, Breast Cancer, Schizophrenia & Psychotropics

The Lancet Psychiatry gives a startling and important summary concerning the link between breast cancer in adult females and their schizophrenia diagnosis in, “Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry” (Taipale, Solmi, Lahteenvuo, Tanskanen, Correll & Tiihonen, 2021).

Vikki

Reference

Taipale, H., PhD., Solmi, M., PhD., Lahteenvuo, M., PhD., Tanskanen, A., Ph.D., Correll, C. U., Ph.D., & Tiihonen, J., PhD. (2021). Antipsychotic Use And Risk Of Breast Cancer In Women With Schizophrenia: A Nationwide Nested Case-Control Study In Finland. The Lancet Psychiatry, 8(10), (pp. 883 – 891). Retrieved From Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry

*The adult male population is not immune from a breast cancer diagnosis!